Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet & other non-pharmacological treatments (eg, exercise, wt reduction) is inadequate. Homozygous familial hypercholesterolaemia as an adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are not appropriate. 5-mg tab: Prevention of major CV events in patients estimated to be at high risk for a 1st CV event, as an adjunct correction of other risk factors.
Initially 5 or 10 mg once daily in both statin-naive or patient switched from another HMG-CoA reductase inhibitor. May be adjusted to the next dose level after 4 wk if necessary. Patient w/ severe hypercholesterolaemia at high CV risk (w/ familial hypercholesterolaemia) Max dose: 40 mg. Childn & adolescent 10-17 yr (boy Tanner stage II & above & girl at least 1 yr post-menarche) w/ heterozygous familial hypercholesterolaemia Initially 5 mg daily. Usual dose range: 5-20 mg once daily. Elderly, Asians, moderate to renal impairment Recommended starting dose: 5 mg. Prevention of CV event 20 mg daily.